|
Total (cases)
|
230
|
79
| |
93
|
55
| |
|
Age [years, median (IQR)]
|
64.0 (57.0–69.3)
|
64.0 (56.0–70.0)
|
0.817
|
64.0 (59.0–70.5)
|
63.0 (54.0–69.0)
|
0.337
|
|
Gender [cases (%)]
| | |
0.027
| | |
0.959
|
|
Male
|
140 (60.9)
|
59 (74.7)
| |
68 (73.1)
|
40 (72.7)
| |
|
Female
|
90 (39.1)
|
20 (25.3)
| |
25 (26.9)
|
15 (27.3)
| |
|
BMI [kg/m2, median (IQR)]
|
22.5 (20.5–24.2)
|
23.2 (20.7–25.3)
|
0.100
|
22.3 (20.3–23.9)
|
23.0 (20.7–25.2)
|
0.107
|
|
ASA score [cases (%)]
| | |
0.059
| | |
0.149
|
|
1
|
43 (18.7)
|
6 (7.6)
| |
18 (19.4)
|
5 (9.1)
| |
|
2
|
177 (77.0)
|
68 (86.1)
| |
73 (78.5)
|
47 (85.5)
| |
|
3
|
10 (4.3)
|
5 (6.3)
| |
2 (2.2)
|
3 (5.5)
| |
|
Charlson comorbidity index [cases (%)]
| | |
0.324
| | |
0.356
|
|
0
|
144 (62.6)
|
44 (55.7)
| |
58 (62.4)
|
31 (56.4)
| |
|
1
|
64 (27.8)
|
29 (36.7)
| |
28 (30.1)
|
22 (40.0)
| |
|
≥ 2
|
22 (9.6)
|
6 (7.6)
| |
7 (7.5)
|
2 (3.6)
| |
|
Year of operation [cases (%)]
| | |
0.256
| | |
0.447
|
|
2013–2015
|
114 (49.6)
|
45 (57.0)
| |
55 (59.1)
|
29 (52.7)
| |
|
2016–2017
|
116 (50.4)
|
34 (43.0)
| |
38 (40.9)
|
26 (47.3)
| |
|
Tumor differentiation [cases (%)]
| | |
0.006
| | |
0.421
|
|
Well-moderate
|
82 (35.7)
|
42 (53.2)
| |
41 (44.1)
|
28 (50.9)
| |
|
Poor
|
148 (64.3)
|
37 (46.8)
| |
52 (55.9)
|
27 (49.1)
| |
|
Nerve invasion [cases (%)]
| | |
< 0.001
| | |
0.131
|
|
Yes
|
203 (88.3)
|
44 (55.7)
| |
73 (78.5)
|
37 (67.3)
| |
|
No
|
27 (11.7)
|
35 (44.3)
| |
20 (21.5)
|
18 (32.7)
| |
|
T stage [cases (%)]
| | |
0.001
| | |
0.835
|
|
1
|
61 (26.5)
|
12 (15.2)
| |
15 (16.1)
|
10 (18.2)
| |
|
2
|
158 (68.7)
|
54 (68.4)
| |
73 (78.5)
|
41 (74.5)
| |
|
3
|
11 (4.8)
|
13 (16.5)
| |
5 (5.4)
|
4 (7.3)
| |
|
N stage [cases (%)]
| | |
0.942
| | |
0.886
|
|
0
|
123 (53.5)
|
44 (55.7)
| |
50 (53.8)
|
32 (58.2)
| |
|
1
|
86 (37.4)
|
28 (35.4)
| |
35 (37.6)
|
19 (34.5)
| |
|
2
|
21 (9.1)
|
7 (8.9)
| |
8 (8.6)
|
4 (7.3)
| |
|
AJCC TNM stage [cases (%)]
| | |
0.794
| | |
0.831
|
|
I
|
117 (50.9)
|
37 (46.8)
| |
46 (49.5)
|
30 (54.5)
| |
|
II
|
92 (40.0)
|
35 (44.3)
| |
39 (41.9)
|
21 (38.2)
| |
|
III
|
21 (9.1)
|
7 (8.9)
| |
8 (8.6)
|
4 (7.3)
| |
|
Adjuvant treatment [cases (%)]
| | |
< 0.001
| | |
0.701
|
|
Yes
|
162 (70.4)
|
31 (39.2)
| |
47 (50.5)
|
26 (47.3)
| |
|
No
|
68 (29.6)
|
48 (60.8)
| |
46 (49.5)
|
29 (52.7)
| |
